Epigen Therapeutics is a biopharmaceutical company whose main office is located in Friuli-Venezia Giulia at the Technological Campus of Pordenone. The company is dedicated to the research and development of therapeutic approaches and innovative diagnostic tools in the immuno-oncology field to be made available to cancer patients. Epigen Therapeutics has a Research & Development Unit at the TLS incubator. Epigen Therapeutics’ main activities are:
Expansion of its innovative patented platform for the development and marketing of an anti-cancer cell vaccine (DeMethAvax);
Development of pre-clinical and clinical projects in collaboration with industrial and academic partners, including scientific consulting;
Evaluation in animal models of the therapeutic efficacy of new bio-immunotherapeutic agents, alone or in combination, and characterization of the anti-cancer immune response induced in vivo.
The translational skills of Epigen Therapeutics are based on extensive experience in the fields of cancer epigenetics, immunology and immunotherapy.